Brett D Welch
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$5.8MFederal grants as PI9 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
9 awards · $5.8M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jul 25, 2019 | NIH | SBIR Phase I Oral/Topical D-peptide TNF Inhibitors for Inflammatory Bowel Disease | $107K | NAVIGEN, INC. |
| Sep 18, 2018 | NIH | SBIR Phase I Oral/Topical D-peptide TNF Inhibitors for Inflammatory Bowel Disease | $216K | NAVIGEN, INC. |
| Jul 17, 2018 | NIH | SBIR Phase II Preclinical development of a potent D-peptide RSV inhibitor | $1000K | NAVIGEN, INC. |
| Jul 28, 2017 | NIH | SBIR Phase II Preclinical development of a potent D-peptide RSV inhibitor | $1000K | NAVIGEN, INC. |
| Mar 29, 2017 | NIH | SBIR Phase II Protease-resistant D-peptide Inhibitors of Ebola Virus Entry | $895K | NAVIGEN, INC. |
| Apr 25, 2016 | NIH | SBIR Phase I Highly specific anti-toxin therapies for severe bacterial gut infections | $297K | NAVIGEN, INC. |
| Feb 11, 2016 | NIH | SBIR Phase II Protease-resistant D-peptide Inhibitors of Ebola Virus Entry | $1.0M | NAVIGEN, INC. |
| Apr 16, 2015 | NIH | SBIR Phase I Highly specific anti-toxin therapies for severe bacterial gut infections | $300K | NAVIGEN, INC. |
| Mar 16, 2015 | NIH | SBIR Phase II Protease-resistant D-peptide Inhibitors of Ebola Virus Entry | $1.0M | NAVIGEN, INC. |
Peer ranks
Federal funding#204
Awards as PI#151
Patents#273
Companies
- NAVIGEN, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.